Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mosunetuzumab - Genentech

Next Previous
X
Search
Drug Profile

Mosunetuzumab - Genentech

Alternative Names: Anti-CD20/CD3 T-cell dependent bispecific antibody; BTCT 4465A; CD20-TBD; CD20xCD3 T-cell engaging bispecific antibody; Lunsumio; mosunetuzumab-axgb; RG7828; RO7030816

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma
  • Phase III Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Phase II Marginal zone B-cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I B-cell lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Follicular lymphoma(Second-line therapy or greater) in China (IV, Infusion)
  • 13 Feb 2024 Efficacy and adverse event data from a phase I expanded cohort trial in Follicular lymphoma released by Chugai Pharamceuticals
  • 09 Feb 2024 Chugai Pharamceuticals completes a phase I expanded cohort trial in Follicular lymphoma (Second-line therapy or greater, Refractory disease) in Japan (JapicCTI-183857)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top